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ABSTRACT 
In Korea, the incidence of acute myocardial infarction has been increasing rapidly. Twelve-month clinical outcomes 
for 13,133 patients with acute myocardial infarction enrolled in the nationwide prospective Korea Acute Myocardial 
Infarction Registry study were analyzed according to the presence or absence of ST-segment elevation. Patients with 
ST-segment elevation myocardial infarction (STEMI) were younger, more likely to be men and smokers, and had 
poorer left ventricular function with a higher incidence of cardiac death compared to patients with non-ST-seg-
ment elevation myocardial infarction (NSTEMI). NSTEMI patients had a higher prevalence of 3-vessel and left 
main coronary artery disease with complex lesions, and were more likely to have co-morbidities. The in-hospital 
and 1-month survival rates were higher in NSTEMI patients than in STEMI patients. However, 12-month survival 
rates was not different between the two groups. In conclusion, NSTEMI patients have worse clinical outcomes than 
STEMI patients, and therefore should be treated more intensively during clinical follow-up. (Korean Circ J 2009; 
39:297-303) 
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Introduction 
 
The present study reveals 12-month clinical outcomes 
for 13,133 patients with acute myocardial infarction 
(AMI) who were enrolled in the nationwide prospective 
Korea Acute Myocardial Infarction Registry (KAMIR) 
between November 2005 and December 2007. Laun-
ched in November 2005, the KAMIR is the first na-
tionwide, population based, multicenter data collection 
registry in Korea designed to track outcomes of patients 
presenting with AMI. The registry includes 52 commu-
nity and teaching hospitals that enroll more than 10,000 
patients annually. As of March 2009, the registry con-
tained data on 21,871 patients. Centers included in the 
registry were chosen based on a careful evaluation of lo-
cal demographics and care facilities. Since treatment 
decisions for patients included in the KAMIR are at 
the discretion of the patient’s physician, data collected 
in the registry reflect a real-world approach to the diag-
nosis and treatment of AMI in Korea. The KAMIR is 
supported by a research grant from the Korean Society 
of Circulation in commemoration of its 50th Anni-
versary and aims to improve patient care by providing 
a greater understanding of patient management and 
outcomes in the rapidly evolving field of AMI treatment. 
Recently in Korea the proportion of non-ST-segment 
elevation myocardial infarction (NSTEMI) has been in-
creasing, compared with acute ST-segment elevation my-
ocardial infarction (STEMI). We sought to evaluate dif-
ferences between STEMI and NSTEMI in laboratory 
and clinical outcomes through the KAMIR in Korean 
patients. 
 
Comparison of Clinical Outcomes  
Between ST-Segment Elevation 
Myocardial Infarction and Non-ST- 
Segment Elevation Myocardial 
Infarction 
 
Patients entered into the registry were  ≥18 years of 
age at the time of hospital presentation, had to be ad-
mitted with an AMI as the presumptive diagnosis, and 
had  ≥1 of the following: electrocardiographic changes 
consistent with an AMI, serial increases in serum bio-
chemical markers of myocardial necrosis, and/or docu-
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mentation of coronary artery disease. 
The primary clinical end point was the composite of 
major adverse cardiac events (MACE), including death 
from any cause, myocardial infarction, target vessel/le-
sion revascularization, and coronary artery bypass graft-
ing (CABG) during a 12-month clinical follow-up. 
Characteristics were examined separately for STEMI 
and NSTEMI patients (Table 1 and 2). STEMI patients 
were younger, more likely to be men and smokers, and 
had poorer left ventricular function with a higher in-
Table 1. Baseline clinical characteristics 
  STEMI (n=7,855)  NSTEMI (n=5,278)  p 
Age (years)  62.0±12.8 64.3±12.3  
Age group, n (%)       
<55  2,339 (29.8)  1,214 (23.0)  <0.001 
55-64  1,889 (24.0)  1,214 (23.0)  <0.166 
65-74  2,200 (28.0)  1,692 (32.1)  <0.001 
≥75  1,427 (18.2)  1,158 (21.9)  <0.001 
Men, n (%)  5,800 (73.6)  3,468 (65.4)  <0.001 
Medical history, n (%)       
Ischemic heart disease  948 (12.1)  1,206 (22.9)  <0.001 
Hypertension  3,577 (46.1)  2,855 (54.4)  <0.001 
Diabetes  1,947 (25.2)  1,707 (32.6)  <0.001 
Hypercholesterolemia  622 (9.1)  653 (14.1)  <0.001 
Current smoking  4,793 (61.4)  2,704 (51.6)  <0.001 
Family history  514 (7.4)  335 (7.0)  <0.443 
CVA history  469 (5.9)  471 (8.9)  <0.001 
Heart failure  107 (1.4)  213 (4.0)  <0.001 
Peripheral artery disease  61 (0.8)  81 (1.5)  <0.001 
LVEF (%)  50.3±14.7 53.8±23.6  <0.001 
CVA: cerebrovascular accident, LVEF: left ventricular ejection fraction, STEMI: ST-segment elevation myocardial infarction, NSTEMI: non-ST-
segment elevation myocardial infarction. 
   
Table 2. Coronary angiographic findings 
  STEMI (n=7,290)  NSTEMI (n=4,385)  p 
Number of involved vessels, n (%)       
1 vessel disease  3,335 (45.7)  1,529 (34.9)  <0.001 
2 vessel disease  2,188 (30.0)  1,363 (31.1)  <0.224 
3 vessel disease  1,592 (21.8)  1,305 (29.8)  <0.001 
Left main (complex)  150 (2.1)  167 (3.8)  <0.001 
Left main (isolated)  25 (0.3)  21 (0.5)  <0.256 
Infarct related artery, n (%)       
Left main  115 (1.6)  148 (3.4)  <0.001 
Left anterior descending  3,735 (51.2)  1,784 (41.0)  <0.001 
Left circumflex  706 (9.7)  1,218 (28.0)  <0.001 
Right coronary  2,742 (37.6)  1,203 (27.6)  <0.001 
ACC/AHA lesion classification, n (%)       
Type A  307 (4.5)  226 (5.6)  <0.010 
Type B1  1,204 (17.7)  752 (18.7)  <0.185 
Type B2  1,809 (26.6)  1,179 (29.4)  <0.002 
Type C  3,470 (51.1)  1,854 (46.2)  <0.001 
TIMI flow       
TIMI 0  3,704 (53.1)  1,183 (28.8)  <0.001 
TIMI 1  747 (10.7)  537 (13.1)  <0.001 
TIMI 2  1,030 (14.8)  754 (18.4)  <0.001 
TIMI 3  1,500 (21.5)  1,631 (39.7)  <0.001 
STEMI: ST-segment elevation myocardial infarction, NSTEMI: non-ST-segment elevation myocardial infarction, ACC/AHA: American College
of Cardiology/American Heart Association, TIMI: thrombolysis in myocardial infarction    
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cidence of cardiac death, compared to NSTEMI patients 
(Table 3 and 4). NSTEMI patients had a higher preva-
lence of 3-vessel and left main coronary artery disease 
with complex lesions, and were more likely to have co-
morbidities (Table 1 and 2).  
The in-hospital and 1-month survival rates were high-
er in patients with NSTEMI than in patients with STEMI 
(Figs. 1 and 2). However, 12-month survival rate was not 
different between patients with NSTEMI and STEMI 
(Fig. 3). 
Predictors of mortality in STEMI patients during 12- 
month follow up were presence of ventricular tachycar-
dia/fibrillation, decreased left ventricular function, mul-
ti-vessel disease, and age (Table 5). In NSTEMI patients, 
Table 4. Twelve-month MACEs 
  STEMI (n=5,110)  NSTEMI (n=3,315)  p 
12-month MACE, n (%)       
Cardiac death  630 (12.3)  315 (9.5)  0.009
Non-cardiac death  67 (1.3)  61 (1.8)  0.681 
Myocardial infarction  51 (1.0)  63 (1.9)  0.072 
Repeat PCI  389 (7.6)  210 (6.3)  0.110 
Target vessel revascularization  69 (1.5)  42 (1.4)  0.516 
Non-target vessel revascularization  190 (3.7)  94 (2.8)  0.227 
Target lesion revascularization  138 (2.7)  79 (2.3)  0.574 
Coronary artery bypass grafting  25 (0.5)  27 (0.8)  0.132 
Composite MACE  1162 (22.7)  676 (20.4)  0.121 
PCI: percutaneous coronary intervention, STEMI: ST-segment elevation myocardial infarction, NSTEMI: non-ST-segment elevation myocardial 
infarction, MACEs: major adverse cardiac events 
   
Table 3. In-hospital mortality and one-month MACEs 
  STEMI (n=7,890)  NSTEMI (n=5,103)  p 
In-hospital death, n (%)  504 (6.4)  199 (3.8)  <0.001 
1-month MACE, n (%)       
Cardiac death  571 (8.5)  255 (5.7)  <0.001 
Non-cardiac death  27 (0.4)  19 (0.4)  <0.501 
Myocardial infarction  30 (0.4)  33 (0.7)  <0.821 
Repeat PCI  62 (1.0)  37 (0.9)  <0.324 
Target vessel revascularization  18 (0.2)  14 (0.2)  <0.648 
Non-target vessel revascularization  41 (0.5)  22 (0.4)  <0.303 
Target lesion revascularization  16 (0.2)  10 (0.2)  <0.973 
Coronary artery bypass grafting  16 (0.2)  20 (0.4)  <0.254 
Composite MACE  705 (10.4)  364 (8.2)  <0.003 
PCI: percutaneous coronary intervention, STEMI: ST-segment elevation myocardial infarction, NSTEMI: non-ST-segment elevation myocardial 
infarction, MACEs: major adverse cardiac events 
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Fig. 2. One-month survival rate was higher in non-ST-segment el-
evation myocardial infarction (NSTEMI) patients than in ST-seg-
ment elevation myocardial infarction. (STEMI) patients.  
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Fig. 1. In-hospital survival rate was higher in non-ST-segment el-
evation myocardial infarction (NSTEMI) patients than in ST-seg-
ment elevation myocardial infarction (STEMI) patients.  
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ventricular tachycardia/fibrillation, decreased left ven-
tricular function, and multi-vessel disease were associated 
with 12-month all-cause mortality (Table 5). 
In both groups, a high percentage of patients received 
drug-eluting stents (DES), the outcomes of which were 
superior to those of bare-metal stents (BMS) with signifi-
cantly lower rates of death and target lesion revasculariz-
ation at 12-month follow-up (Table 6). Among patients 
who underwent DES implantation, 12-month clinical 
outcomes were similar between patients treated with si-
rolimus-eluting stents (Cypher stent, Cordis, Johnson & 
Johnson, Miami Lakes, FL, USA) and paclitaxel-elut-
ing stents (Taxus stent, Boston Scientific Corp, Natick, 
MA, USA) (Table 7) (Fig. 4). 
One of the main limitations of this study is that the 
proportion of patients followed up was relatively low 
with 63.0% at 6 months and 52.5% at 12 months. Al-
though our follow-up rate was less than the rate typically 
observed in randomized trials, the characteristics of pa-
tients lost to follow-up were relatively similar to those 
remaining under observation. 
 
Discussion 
 
According to the KAMIR, the in-hospital survival rate 
was higher in NSTEMI patients than in STEMI patients. 
However, the 1-year survival rate was not different be-
tween the two groups, indicating that in the Korean pop-
ulation NSTEMI patients should be treated as inten-
sively as STEMI patients during clinical follow-up. 
The KAMIR study, launched in commemoration of 
the 50th anniversary of the Korean Society of Circula-
Table 5. Predictors of mortality during 12-month clinical follow-up in NSTEMI and STEMI patients
STEMI  NSTEMI 
Variables 
HR (95% CI)  p  HR (95% CI)  p 
Age        
≤55 1.0  <0.014   <0.477 
55-64 0.34  (0.18-0.67)  <0.002  <0.217 
65-74   <0.070  <0.195 
≥75   <0.067   <0.557 
Medical history         
Myocardial infarction    <0.140   <0.140 
Previous PCI    <0.460   <0.635 
Heart failure    <0.171   <0.927 
Complications during hospitalization         
Heart failure    <0.445   <0.753 
Acute renal failure    <0.571   <0.150 
Atrioventricular block    <0.616   <0.326 
Ventricular tachycardia/fibrillation  2.41 (1.41-4.13)  <0.001 5.78  (2.51-13.31)  <0.001 
LVEF decrease  2.20 (1.51-3.22)  <0.001 2.15  (1.45-3.20)0  <0.001 
Multi-vessel disease  1.38 (1.13-1.68)  <0.001 1.49  (1.23-1.83)0  <0.001 
STEMI: ST-segment elevation myocardial infarction, NSTEMI: non-ST-segment elevation myocardial infarction, PCI: percutaneous coronary 
intervention, LVEF: left ventricular ejection fraction, HR: hazard ratio, CI: confidence interval     
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Fig. 3. Twelve-month survival rates were not different between
non-ST-segment elevation myocardial infarction (NSTEMI) patients
and ST-segment elevation myocardial infarction (STEMI) patients.
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Fig. 4. Post-discharge survival at 12 months after implantation of
Cypher and Taxus stents was not different between the two drug-
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tion, is the first large-scale, nationwide multicenter trial 
in Korea and has value in helping clinicians understand 
the real-world epidemiology and management status of 
AMI in the Korean population. Intensive follow-up and 
surveillance of the enrollees, as suggested above, is an 
essential requisite for the ultimate goal of the KAMIR, 
i.e., establishment of a validated prediction model for 
mortality risk and prognosis in patients with AMI. 
Since its inception in 2005, this study has generated 
over 100 published papers and invited high-profile in-
ternational conference presentations. So far, as many as 
11 scientific papers have been published in leading in-
ternational journals. Lee et al.
1) proved that the rates of 
MACE and stent thrombosis at 6 months after discharge 
were not different between the two types of DES, i.e. Cy-
pher and Taxus stents, indicating that DES can be safely 
used in patients with AMI. Song et al.
2) reported that 
1-month mortality was not associated with initial time 
variables to reperfusion, suggesting that patient progno-
sis may not depend on the initial treatment delay in the 
current practice of primary percutaneous coronary in-
tervention (PCI) in Korea. Jeong et al.
3) indicated that 
intensive pharmacologic treatment may improve short-
term clinical outcomes in NSTEMI patients who were 
not indicated for PCI. Lee et al.
4) reported that clinical 
outcomes were dependent on the status of estimated glo-
merular filtration rate (GFR) in patients who under-
went invasive treatment. They also suggested that high 
waist-to hip ratio and underweight are mortality risk fac-
tors in STEMI patients.
5) Lee et al.
6) observed that the 
success rate of PCI for NSTEMI was lower and 1-month 
MACE for both STEMI and NSTEMI were higher in 
females than males, even though there was no gender dif-
ference in the initial treatment of strategy AMI. Kwon 
et al.
7) r eported that baseline N-terminal pro-B type 
natriuretic peptide (NT-proBNP) level was associated 
with shortterm mortality in STEMI patients who un-
derwent primary PCI, and that NT-proBNP level on ad-
mission could be used as a prognostic factor in STEMI 
patients treated with primary PCI. Lee et al.
8) reported 
that the incidence of AMI showed seasonal and month-
ly variations and that meteorological parameters had a 
significant influence on the occurrence of AMI, partic-
ularly in females and in patients of younger age. They 
Table 6. Twelve-month MACEs between bare-metal and drug-eluting stents
(%)  Bare-metal stents (n=650)  Drug-eluting stents (n=5,948)  p 
Stent size (mm)  21.6±5.6 25.3±6.4  <0.001 
Stent diameter (mm)  03.4±0.6  03.1±0.4  <0.001 
12-month MACE       
Cardiac death  66 (10.2)  105 (6.8)  <0.006 
Non-cardiac death  20 (3.1)  68 (1.1)  <0.001 
Myocardial infarction  6 (0.9)  60 (1.0)  <0.876 
Repeat PCI  68 (10.5)  478 (8.0)  <0.009 
Target vessel revascularization  11 (1.7)  89 (1.5)  <0.595 
Non-target vessel revascularization  20 (3.0)  240 (4.0)  <0.018 
Target lesion revascularization  40 (6.1)  159 (2.6)  <0.001 
Coronary artery bypass grafting  2 (0.3)  17 (0.3)  <0.719 
Composite MACE  162 (24.9)  1,025 (17.4)  <0.001 
PCI: percutaneous coronary intervention, MACEs: major adverse cardiac events 
 
Table 7. Twelve-month MACEs between Cypher and Taxus stents
(%)  Cypher (n=2,892)  Taxus (n=2,233)  p 
Stent size (mm)  26.2±6.6 25.2±6.3  <0.001 
Stent diameter (mm)  03.1±0.4  03.2±0.4  <0.014 
12-month MACE       
Cardiac death  178 (6.2)  143 (6.4)  <0.597 
Non-cardiac death  33 (1.1)  22 (1.0)  <0.071 
Myocardial infarction  30 (1.0)  26 (1.2)  <0.576 
Re-PCI  203 (7.0)  195 (8.7)  <0.282 
Target vessel revascularization  45 (1.5)  30 (1.3)  <0.139 
Non-target vessel revascularization  108 (3.7)  100 (4.5)  <0.627 
Target lesion revascularization  54 (1.8)  69 (3.0)  <0.153 
Coronary artery bypass grafting  7 (0.2)  5 (0.2)  <0.192 
Composite MACE  451 (15.6)  391 (17.5)  <0.962 
MACEs: major adverse cardiac events, PCI: percutaneous coronary intervention 
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also reported that predictors of 6-month MACE in 30- 
day survivors of AMI included body mass index, severity 
of left ventricular systolic dysfunction, residual myocar-
dial ischemia, and electrical instability.
9) Furthermore, 
Chen et al.
10) demonstrated that triple anti-platelet in-
cluding aspirin, clopidogrel, and cilostazol was superior 
to conventional dual anti-platelet therapy in preventing 
MACE without increasing bleeding complications in 
pa-tients with AMI undergoing PCI. Sim et al.
11) eval-
uated the safety and benefit of early, elective PCI after 
thrombolytic therapy for AMI and reported that PCI 
within 48 hours of successful fibrinolysis was safe and 
more beneficial compared with PCI performed later. 
Cho et al.
12) identified risk factors for AMI in young 
Korean patients. Lee et al.
13) reported that hypertensive 
AMI patients with diabetes had worse prognoses than 
those without diabetes. 
Analyses and research continue to the present day. 
The results have also provided impetus for a subsequent 
study, the Korea Working Group on Myocardial In-
farction (KorMI). The KorMI, which is a continuation 
of the KAMIR, is an ongoing, open-ended registry that 
captures data on the complete spectrum of patients ex-
periencing AMI, including long-term clinical follow-up. 
The KAMIR Scientific Committee and the Korean So-
ciety of Cardiology are actively discussing the transfor-
mation of the KorMI into a regular working group to 
ensure continuity and stability. It is the strong feeling 
of the KAMIR Scientific Committee that the KorMI 
should evolve into a regular society immediately, based 
on the success of the KAMIR from 2005 and on the 
fruitful results it has since achieved. 
A clear understanding of the key messages the KAMIR 
delivers to the cardiology community will serve as a step-
ping stone to better care and treatment of AMI in the 
Korean population. The observation that hypertension 
and smoking were the most prevalent risk factors in the 
KAMIR population warrants establishing more aggres-
sive management of hypertension and a more vigorous 
country-level campaign against cigarette smoking. In ad-
dition, it is mandatory to promote continuous public 
awareness about the importance of early access to treat-
ment in order to reduce the time delay in seeking medi-
cal attention from the onset of perceived symptoms. 
 
Conclusion 
 
The number of patients surviving AMI is on a steady 
rise with the use of new drug therapies and non-drug 
interventions. Overall in-hospital mortality of AMI pa-
tients is about 5% in Korea. The proportion of NSTEMI 
patients is increasing and there is a growing need for 
intensive surveillance and rehabilitation programs, es-
pecially for this subset of AMI patients. The KAMIR, 
with continued expansion and successful growth, will 
make an invaluable contribution to the long-term care 
and monitoring of outcomes in Korean patients with 
AMI.  
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